Skin cancer survivors test cream combo to stop new tumors
NCT ID NCT04091022
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a combination of two FDA-approved creams (diclofenac and DFMO) can prevent new non-melanoma skin cancers in people who have already had them. 64 participants applied the creams or a placebo to their arms for 9 months. The goal was to see if the treatment reduced the number of precancerous spots and new skin cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
topical diclofenac 3% cream and topical eflornithine (DFMO) 13.9% cream
What this could lead to
If successful, this combination cream could offer a new way to prevent non-melanoma skin cancers from forming in people who have already had them.
What could go wrong
This is a small, early-phase trial (64 participants) testing a combination of two existing drugs for a new purpose. The results may not be strong enough to change practice, and skin irritation from the creams is possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MELANOMA SKIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Birmingham VA Medical Center
Birmingham, Alabama, 35233, United States
-
UAB Dermatology
Birmingham, Alabama, 35233, United States